Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial

Atezolizumab plus modified docetaxel-cisplatin-5-fluorouracil (mDCF) regimen versus mDCF in patients with metastatic or unresectable locally advanced recurrent anal squamous cell carcinoma: a randomized, non-comparative phase II SCARCE GERCOR trial

Abstract Background Modified docetaxel, cisplatin, and 5-fluorouracil (mDCF) regimen has become a new standard for the treatment of metastatic or unresectable locally advanced recurrent squamous cell carcinoma of the anus (SCCA) after demonstrating improved efficacy (12-month PFS of 47%) in the Epit...

Full description

Bibliographic Details
Main Authors: Stefano Kim, Bruno Buecher, Thierry André, Marine Jary, François-Clément Bidard, François Ghiringhelli, Éric François, Julien Taieb, Denis Smith, Christelle de la Fouchardière, Jérôme Desramé, Emmanuelle Samalin, Aurélie Parzy, Nabil Baba-Hamed, Olivier Bouché, David Tougeron, Laëtitia Dahan, Farid El Hajbi, Marion Jacquin, Magali Rebucci-Peixoto, Laurie Spehner, Véronique Vendrely, Dewi Vernerey, Christophe Borg
Format: Article
Language:English
Published: BMC 2020-04-01
Series:BMC Cancer
Subjects:
Anal carcinoma
Advanced
Atezolizumab
Chemotherapy
Immunotherapy
Docetaxel
Online Access:http://link.springer.com/article/10.1186/s12885-020-06841-1

Internet

http://link.springer.com/article/10.1186/s12885-020-06841-1

Similar Items